The development of trivalent CAR-Ts specific to IL13Rα2, the human epidermal growth factor receptor (HER-2) and EGFRvIII, was made possible by analysing interpatient variability of multiple GBM samples, showing tumor cell-specific cytotoxicity and tumor remission in vitro and in vivo models [79]. Here, ERBB2 is linked to glioblastoma.